Davis Polk advised Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC and Jefferies LLC as representatives of the several underwriters in connection with the SEC-registered follow-on offering of 8,222,500 shares of common stock of Durata Therapeutics, Inc., including 1,072,500 shares from the full exercise of the underwriters’ option to purchase additional shares, for a price to the public of approximately $57.6 million.
Based in Chicago, Illinois, Durata is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. It recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI.
The Davis Polk corporate team included partner Richard D. Truesdell Jr., associates Alain Kuyumjian, Sarah Whittington and Bin Hu and law clerk Daniel Bremmer. The intellectual property team included associate David R. Bauer and law clerk Dan Karmel. Partner Samuel Dimon and associate Kerry S. Price provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Rosemarie Melendez was the legal assistant for the transaction. All members of the Davis Polk team are based in the New York office.
